Hemoglobin A1c Reduction With the GLP-1 Receptor Agonist Semaglutide Is Independent of Baseline eGFR: post hoc Analysis of the SUSTAIN and PIONEER Programs

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for reducing hemoglobin A1c (HbA1c) in people with type 2 diabetes (T2D), including those with reduced kidney function. METHODS: This post hoc analysis assessed the HbA1c-lowering efficacy of semaglutide, a G...

Descripción completa

Detalles Bibliográficos
Autores principales: Cherney, David Z.I., Hadjadj, Samy, Lawson, Jack, Mosenzon, Ofri, Tuttle, Katherine, Vrhnjak, Blaz, Rasmussen, Søren, Bain, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751689/
https://www.ncbi.nlm.nih.gov/pubmed/36531884
http://dx.doi.org/10.1016/j.ekir.2022.07.167

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751689/
https://www.ncbi.nlm.nih.gov/pubmed/36531884
http://dx.doi.org/10.1016/j.ekir.2022.07.167

Ejemplares similares